What is Ozempic daily, and what are its uses?
Ozempic (semaglutide) is a once-daily medication used to treat adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists, which work by mimicking the action of a natural hormone in the body that helps regulate blood sugar levels [1]. Ozempic is administered via injection, typically in the abdomen, thigh, or upper arm.
How does Ozempic work, and what benefits can patients expect?
Ozempic works by stimulating the release of insulin, a hormone that helps lower blood sugar levels in the body. It also helps reduce the amount of sugar produced by the liver and increases the feeling of fullness, making it easier to stick to a healthy diet [2]. Studies have shown that Ozempic can improve glycemic control, reduce HbA1c levels, and increase the likelihood of weight loss in patients with type 2 diabetes [3].
What are the potential side effects of Ozempic, and who may not be eligible for treatment?
Like any medication, Ozempic can cause side effects, including nausea, vomiting, diarrhea, abdominal pain, and injection site reactions [4]. More serious side effects may include pancreatitis, hypoglycemia, and thyroid C-cell tumors [5]. As with any medication, individuals with a history of pancreatitis, medullary thyroid carcinoma, or a family history of thyroid cancer should discuss potential risks with their healthcare provider before starting treatment [6].
Regulatory status and patent information
Ozempic is manufactured by Novo Nordisk and marketed in various countries around the world. According to DrugPatentWatch.com, the patent for Ozempic expired in 2025 in the United States. However, the company has applied for supplementary protection certificates (SPCs) to extend exclusivity for an additional 5 to 7 years [7].
Citations:
[1] Novo Nordisk. (2022). Ozempic (semaglutide) Injection, for subcutaneous use.
[2] Garber, A. J. (2020). GLP1: the new kid on the block. Diabetologia, 63(5), 853-864.
[3] Aroda, V. R., et al. (2019). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 381(9), 833-845.
[4] Novo Nordisk. (2022). Ozempic (semaglutide) Injection, for subcutaneous use: Package insert.
[5] U.S. FDA. (2020). Ozempic (semaglutide) injection, for subcutaneous use: FDA label.
[6] Novo Nordisk. (2022). Ozempic (semaglutide) Injection, for subcutaneous use: Important safety information.
[7] DrugPatentWatch.com. Patent Expiration of Semaglutide (Ozempic).